NCT00025818已完成3 期
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 290
- 试验地点
- 34
研究概览
简要总结
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune disorder AND/OR females 65 years of age or older.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eighteen years or older
- •Diagnosis of moderate to severe dry eyes for at least 6 months and meet one or all of the following criteria:
- •Diagnosis of autoimmune disorder
- •Female 65 years of age or older
排除标准
- 未提供
研究者
研究点 (34)
Loading locations...
相似试验
已完成
4 期
Replagal Enzyme Replacement Therapy for Adults With Fabry DiseaseFabry DiseaseNCT00097890National Institute of Neurological Disorders and Stroke (NINDS)25
已完成
不适用
Effects of Hintonia latiflora in type 2 diabeticsMild and moderate diabetes mellitus of type II (age-related)Nutritional, Metabolic, EndocrineISRCTN83308122Gehrlicher Pharmazeutische Extrakte GmbH (Germany)40
招募中
不适用
Clinical study over a period of at least 6 months to an individualized strength and endurance training in COPD patients in MarburgerJ44.8Other specified chronic obstructive pulmonary diseaseDRKS00006842Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL)48
已完成
3 期
A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)Restless Legs SyndromeNCT00152958Boehringer Ingelheim224
已完成
3 期
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHDADHDNCT02168127Rhodes Pharmaceuticals, L.P.360